Project Grant R01DK137506
Award Date
8/1/24
Completion Date
5/31/29
Dollars Obligated
$629K
Federal Grant Program
93.847
Assistance Type
Project Grant
Place of Performance
Birmingham, AL 35294, USA
Similar Awards
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) will fund $1,391,142 of research by Function Therapeutics Inc. to develop small molecule "Parmodulins" as a novel treatment for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease characterized by fat accumulation, inflammation, and fibrosis. The project aims to...
This federal Project Grant award, funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), will support research at the Pennington Biomedical Research Center to examine the role of the mitochondrial protein SLC25A25 in the onset and progression of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH)....
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $172,060 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH). The project aims to understand the mechanism by which the Unfolded Protein Response (UPR) is dysregulated in the pathogenesis of Non-Alcoholic Steatohepatitis (NASH), a leading cause of liver...
The federal Project Grant award R01DK140159, funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), aims to investigate the potential of a novel adipokine in resolving non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) in animal models. The $469,235 award, with a start date of September 1, 2024, and an ultimate completion date of June 30,...
This $754,400 Project Grant award was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research (CFDA 93.847) program. The funding will support research by The University of Texas Southwestern Medical Center (UT Southwestern) to identify adaptive genetic pathways and understand how mutant clones expand within chronically damaged liver tissues, with the goal of developing therapeutic approaches...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), aims to define the role of antigen-specific T cell responses in the progression of non-alcoholic steatohepatitis (NASH), a chronic liver disease. The $599,541 award, with a project period from September 2024 to August 2025, will fund research at the University of Colorado-Denver to investigate:...
This $243,590 Project Grant awarded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports research at the University of Chicago to investigate the role of the protein BNIP3 in regulating lipid metabolism and fat accumulation in the liver. The research aims to elucidate the mechanisms by which BNIP3 promotes mitophagy (selective degradation of mitochondria) and...
This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $642,653 to the Trustees of Boston University to develop a novel treatment called "Lysogen" for metabolic dysfunction-associated steatotic liver disease (MASLD). The key products and services to be delivered include: Synthesizing and characterizing Lysogen polymers...
This $806,452 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) supports research investigating the mechanisms that combine type 2 diabetes and non-alcoholic fatty liver disease (NAFLD). The research aims to determine how hepatic insulin resistance can lead to the progression of NAFLD to the more severe non-alcoholic steatohepatitis (NASH), and how this...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $740,040 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to Xylyx Bio, Inc. to develop and commercialize an engineered human liver fibrosis cell-based assay platform. The award supports the creation of a predictive in vitro model that integrates patient-derived liver cells, including stellate cells, Kupffer cells, and hepatocytes, within an...